Biocon Limited · NSE:BIOCON
Biocon — Shareholder Meeting (June 2016)
22 slides from Biocon's shareholder meeting presentation, Jun 30, 2016
Slide 1: 38th Annual General Meeting: Chairperson's Speech
38th Annual General Meeting CHAIRPERSON’S SPEECH June 30th, 2016 Biocon Research Centre Kiran Mazumdar Shaw Chairperson & Managing Director BSE: 532523 | NSE: BIOCON | REUTERS: BION.NS | BLOOMBERG: BIOS IN | WWW.BIOCON.COM
Slide 2: Welcome
Welcome Biocon marks a landmark year of delivering on its ‘Credibly Capable’ promise to patients, partners and shareholders
Slide 3: FY16: A Landmark Year
FY16: A Landmark Year o Insulin Glargine approved in Japan; 1st biosimilar from India to be approved o Biosimilar Trastuzumab, Pegfilgrastim report positive results from global Phase III clinical studies o Syngene IPO makes strong market debut; achieves US$1 Bn valuation in 1st week of listing o Gen
Slide 4: Prepared to Tackle Global Health Challenges
Prepared to Tackle Global Health Challenges NCDs Crisis CANCER Cause of ‘One in Seven’ deaths globally DIABETES Affects ‘One in 11’ Adults globally Rapidly Changing Medical Paradigm Customised One Size Fits All Solutions
Slide 5: Strategic Capabilities
Strategic Capabilities Increase in Insulins Increase in +100% Drug Substance production capacity +200% production capacity for Drug Products Countries where our ~120 products are available Increase in no. of Small ~1.5x Molecule product groups in last 5 years ~2x Increase in no. of DMFs filed in las
Slide 6: Being Credible
Being Credible 1,200+ 984 448 Patent applications Patents granted Trademark registrations filed globally 12 +2x 7 Anchor Brands Biologics taken from Increase in sales from Lab to Market Top 10 brands in last 5 2 Novels & 5 Biosimilars years Excellence In Process & Analytical & Preclinical & Regulato
Slide 7: Fighting Diabetes
Fighting Diabetes Our Objective: To provide Biocon Products to ‘One in Five’ patients in need of insulins o Biocon: A Leading player in Diabetes Diabetes Fact Sheet: Management • 500 million patients globally o Asia’s largest and world’s fourth largest insulins • 100 million need producer insulin o
Slide 8: Battling Cancer
Battling Cancer Cancer Fact Sheet: By 2030 globally, o New cancer cases expected to rise to 22 mn o 13 million deaths annually Biocon: Committed to Affordable Cancer Care o Trastuzumab follow-on biologic, launched in Emerging Markets o Various partnered biosimilar programs with Mylan in advanced sta
Slide 9: Global Biosimilars Pipeline: US$60 Bn Opportunity
Global Biosimilars Pipeline: US$60 Bn Opportunity Market Size* Molecule Status (US$ bn) rh-Insulin EU Phase III complete 3.1 INSULINS Glargine Global Phase III 7.1 Aspart Preclinical/Scale Up 4.7 Lispro Preclinical/Scale Up 2.8 Insulins Total Market Size (rounded off) 18.0 Adalimumab Global Phase II
Slide 10: Biocon, Mylan presented Phase III biosimilar Trastuzumab data at ASCO 2016
2016, Chicago, USA o Biocon, Mylan presented data from global Phase III study of biosimilar Trastuzumab @ASCO o Study confirms biosimilar Trastuzumab equivalent to branded product in terms of efficacy, safety and immunogenicity o Global clinical study one of the 1st in this disease area to show equi
Slide 11: Novel Molecules: Lead Programs
Novel Molecules Insulin Tregopil • Positive Phase I clinical data, sets the stage for further First-in-Class Oral Prandial Insulin development by Biocon LEAD PROGRAMS Itolizumab • Commercialized in India for Psoriasis. Novel, humanized antibody directed at CD6 • Phase I study in normal healthy volun
Slide 12: Unlocking Value: Syngene IPO
Unlocking Value: Syngene IPO Syngene: The ‘Innovation Partner’ o Subscription: IPO Oversubscribed 31x o Allotment Price: INR 250 (Implied market cap US$770mn) o Listing Price: INR 295 o Closing on Listing Day (August 11, 2015): INR 310 (25% premium) o Current Market Cap: US$1.18 bn o Biocon owns 73.
Slide 13: Maintaining a Quality Track Record
Maintaining a Quality Track Record cGMP approvals from 25+ International regulatory agencies Key regulatory approvals from US, EU, Japan, France, Brazil, Mexico, Turkey, GCC etc cGMP approval for New devices facility at Insulins plant in Biocon Park Malaysia inaugurated
Slide 14: Building Talent Excellence
Building Talent Excellence Top 20 +60% Listed among Best Growth in scientific Global Biotech talent pool in the last Employers* 5 years (*Science magazine) ~71% ~57% Employees under Increase in the Middle 30 years of age Management employees in the last 5 years ~3x ~26% Increase in no. of Rise in Ma
Slide 15: Expanding Management Bandwidth
Expanding Management Bandwidth Welcome! Dr. Narendra Chirmule Senior VP & Head, R&D, Biocon SYNGENE – New CEO Mr. Jonathan Hunt CEO, Syngene International A Big Thank You! Mr. Peter Bains continues to be on the board of Syngene International
Slide 16: Strengthening the Board
Strengthening the Board Mr. M. Damodaran Appointed as Independent Director Former Chairman, SEBI, UTI, IDBI A renowned Financial Expert, has served both Central and State Govts in critical positions o Founder Chairman of IIM, Tiruchirapalli and Chairman of Glocal Healthcare Systems Pvt Ltd, which pr
Slide 17: Financial Highlights
Financial Highlights o Biocon’s Consolidated Quarterly revenues crossed Rs 10,000 mn for the first time in Q4FY16 o FY16 Revenue at Rs 35699 mn grew 14% o Bottom-line up 80% at Rs 8961 mn* with exceptional income o EBITDA up 21%, with healthy margin of 25% o Net R&D Spends at Rs 2750 mn up 63% o Syn
Slide 18: Beyond Business: CSR
Beyond Business: CSR Promoting Social and Economic Inclusion Expanded footprint entered Rajasthan Healthcare Malnutrition, Oral & Cervical Cancer CSR Education Chinnara Ganitha: Over Community 100,000 workbooks Development Education distributed Biocon employees dedicating Sanitation an hour each wee
Slide 19: Making A Difference
Health Initiative: o Malnutrition: Responsible for 50% of Making A Difference childhood deaths o Providing Nutritional Supplements and monitoring health profiles of undernourished children o Oral Cancer : 8,500 people screened o Cervical Cancer : 800 women screened o Diabetes & Hypertension programs
Slide 20: Biocon Academy: Centre of Excellence
Biocon Academy : Centre of Excellence o Train & develop industry ready talent o Enable Global competitiveness Biocon-KGI Certificate Program in Biosciences o 5 batches completed o Over 150 students employed with multiple biotech and pharma companies (till end of FY16) Biocon-BITS Certificate Program
Slide 21: Looking Ahead
Looking Ahead o Geared to address large biosimilars opportunity o Front runner in biosimilars development for global markets o Generic Formulations business expected to gather momentum in FY17 o Expect attractive returns on our long-term investments in innovative R&D o Syngene: To accelerate revenue
Slide 22: Thank You
Thank You www.biocon.com Developed and Released by Biocon Corporate Communications: Jun 2016